In Vivo Activation of a Conserved MicroRNA Program Induces Mammalian Heart Regeneration
Aitor Aguirre(Michigan State University), Juan Carlos Izpisúa Belmonte(RAM Laboratories (United States)), Núria Montserrat(Institució Catalana de Recerca i Estudis Avançats), Eric Vazquez-Ferrer(Salk Institute for Biological Studies), Ignacio Sancho-Martinez(Salk Institute for Biological Studies), John R. Yates(Scripps Research Institute), Leo Kurian(Goethe University Frankfurt), Mauro Giacca(King's College London), Josep M. Campistol(Universitat de Barcelona), Emmanuel Nivet(Centre National de la Recherche Scientifique), Tomoaki Hishida(Salk Institute for Biological Studies), James J. Moresco(Southwestern Medical Center), Alejandro Ocampo(University of Lausanne), Sachin Kumar(Shree Guru Gobind Singh Tricentenary University), Concepción Rodrı́guez-Esteban(Salk Institute for Biological Studies), Marie N. Krause(Salk Institute for Biological Studies), Serena Zacchigna(University of Trieste)
Cited by 3
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2
|Cell|2020|2.3k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k